Search Results - "Lohuis, Caitlin Ten"
-
1
Protocol Compliance Guiding Angiotensin II Use in Post Cardiovascular Surgery Vasoplegia
Published in Critical care explorations (13-05-2022)“…OBJECTIVES: Catecholamines and vasopressin are commonly used in patients with post cardiovascular surgery vasoplegia (PCSV). Multimodal therapy, including…”
Get full text
Journal Article -
2
Association of Active Renin Content With Mortality in Critically Ill Patients: A Post hoc Analysis of the Vitamin C, Thiamine, and Steroids in Sepsis (VICTAS) Trial
Published in Critical care medicine (01-03-2024)“…Sepsis is a leading cause of mortality. Predicting outcomes is challenging and few biomarkers perform well. Defects in the renin-angiotensin system (RAS) can…”
Get full text
Journal Article -
3
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study
Published in BMJ (Online) (09-03-2022)“…To characterize the clinical severity of covid-19 associated with the alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital and to…”
Get more information
Journal Article -
4
Angiotensin II for Vasodilatory Hypotension in Patients Requiring Mechanical Circulatory Support
Published in Journal of intensive care medicine (01-05-2023)“…Background: Patients supported on mechanical circulatory support devices experience vasodilatory hypotension due to high surface area exposure to nonbiological…”
Get full text
Journal Article -
5
Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19
Published in Journal of critical care (01-02-2025)“…Plasma dipeptidyl peptidase-3 (DPP3) and renin levels are associated with organ dysfunction and mortality. However, whether these biomarkers are associated…”
Get full text
Journal Article -
6
Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States
Published in Vaccine (15-11-2022)“…•The test-negative design has been widely used for evaluating COVID-19 vaccine effectiveness, yet there is an absence of evidence on comparability with…”
Get full text
Journal Article -
7
Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States
Published in Clinical infectious diseases (03-10-2022)“…Abstract Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson…”
Get full text
Journal Article -
8
441: THE EFFECT OF ANGIOTENSIN II IN VENOVENOUS VERSUS VENOARTERIAL EXTRACORPOREAL MEMBRANE OXYGENATION
Published in Critical care medicine (01-01-2022)Get full text
Journal Article -
9
1485: RAAS THERAPY AND CATECHOLAMINE DOSE IN PROPENSITY SCORE-WEIGHTED SEPTIC SHOCK PATIENTS
Published in Critical care medicine (01-01-2024)Get full text
Journal Article -
10
1484: RAAS VERSUS NON-RAAS THERAPY IN PROPENSITY SCORE-WEIGHTED SEPTIC SHOCK PATIENTS
Published in Critical care medicine (01-01-2024)Get full text
Journal Article -
11
1380: A NOVEL PROPENSITY-SCORE-WEIGHTING METHOD FOR RAAS VERSUS NON-RAAS THERAPY IN SEPTIC SHOCK PATIENTS
Published in Critical care medicine (01-01-2024)Get full text
Journal Article -
12
1500: ANGIOTENSIN II FOR DISTRIBUTIVE SHOCK IN PATIENTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES
Published in Critical care medicine (01-01-2022)Get full text
Journal Article -
13
1485: SYNTHETIC ANGIOTENSIN II USE DURING TEMPORARY MECHANICAL CIRCULATORY SUPPORT
Published in Critical care medicine (01-01-2022)Get full text
Journal Article -
14
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021
Published in MMWR. Morbidity and mortality weekly report (24-09-2021)“…Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and…”
Get full text
Journal Article Newsletter -
15
Effectiveness of the Original Monovalent Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Against Hospitalization for COVID-19–Associated Venous Thromboembolism
Published in The Journal of infectious diseases (15-10-2024)“…Abstract Background Coronavirus disease 2019 (COVID-19) is a strong risk factor for venous thromboembolism (VTE). Few studies have evaluated the effectiveness…”
Get full text
Journal Article -
16
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021
Published in MMWR. Morbidity and mortality weekly report (27-08-2021)“…Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination;…”
Get full text
Journal Article Newsletter -
17
-
18
Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States
Published in Clinical infectious diseases (17-05-2022)Get full text
Journal Article -
19
Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States
Published in Clinical infectious diseases (06-08-2021)Get full text
Journal Article -
20
Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States
Published in Clinical infectious diseases (03-05-2022)“…Abstract Background As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to…”
Get full text
Journal Article